# Title

 Food and Drugs. PART 99â€”DISSEMINATION OF INFORMATION ON UNAPPROVED/NEW USES FOR MARKETED DRUGS, BIOLOGICS, AND DEVICES


# ID

 CFR-2018-title21-vol1.Pt. 99


# Structured Analysis Summary

| Type        | Values                                                                                                                                                    |
|:------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['before', 'exceeds', 'within', 'no later than', 'after', 'minimum', 'exceed', 'prior to']                                                                |
| Duration    | ['1.0 year', '6.0 month', '60 day', '60.0 day', '36.0 month', '3.0 year', '24.0 month']                                                                   |
| Condition   | ['unless', 'not subject to', 'where', 'if not', 'subject to', 'when', 'provided that', 'if']                                                              |
| Entities    | ['United States', 'Advertising', 'Scope', 'Agency', 'G112', 'Such', 'Food', 'Request', 'Rm', 'Information', 'Research', 'Rockville, MD', 'New', 'Health'] |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                                                   |
|:--------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------|
| within        | subject to State law which regulates insurance ( within the meaning of section 514(b)(2) of the Employee                                                  |
| after         | the dissemination was conducted up through 1 year after the time the article/reference publication was written and                                        |
| before        | (a) Sixty days  before disseminating any written information concerning the safety, effectiveness,                                                        |
| no later than | new use to the Food and Drug Administration no later than  [insert date                                                                                   |
| no later than | new use to the Food and Drug Administration no later than  [insert date                                                                                   |
| no later than | new use to the Food and Drug Administration no later than  [insert date                                                                                   |
| no later than | new use to the Food and Drug Administration no later than  [insert date                                                                                   |
| no later than | new use to the Food and Drug Administration no later than  [insert date                                                                                   |
| prior to      | (a) A manufacturer may request,  prior to or at the time of making a submission                                                                           |
| within        | be completed and submitted in a supplemental application within  36 months.                                                                               |
| within        | submit a supplemental application for a new use within a specified period of time from the date                                                           |
| within        | submit a supplemental application for a new use within a specified period of time from the date                                                           |
| exceed        | The requested extension shall not  exceed  an additional 24 months.                                                                                       |
| minimum       | a new use, the manufacturer shall, at a minimum , provide: (i) Evidence explaining why existing data                                                      |
| exceeds       | study or studies for the new use reasonably exceeds the expected revenue from the new use minus                                                           |
| after         | Within 60 days  after receiving a submission under this part, FDA may:                                                                                    |
| after         | Within 60 days  after receiving a submission under this part, FDA may:                                                                                    |
| after         | Within 60 days  after receiving a submission under this part, FDA shall:                                                                                  |
| within        | that such studies cannot be completed and submitted within  36 months.                                                                                    |
| before        | to any time limit, but shall be made before the manufacturer begins the studies needed for the                                                            |
| after         | (b) The manufacturer may,  after beginning the studies needed for the submission of                                                                       |
| after         | FDA may grant or deny the request or,  after consulting the manufacturer, grant an extension different from                                               |
| exceed        | Extensions under this paragraph shall not  exceed  24 months.                                                                                             |
| after         | supplemental application under paragraph (a) of this section after the manufacturer has submitted a certification under &#167;&#8201;99.201(a)(4)(ii)(B), |
| within        | certification under &#167;&#8201;99.201(a)(4)(ii)(B) that sets forth the timeframe within which clinical studies will be completed and a                  |
| within        | application, FDA shall approve or deny the application. within                                                                                            |
| after         | (a) Within 60 days  after receipt of an application for an exemption from                                                                                 |
| within        | not act on the application for an exemption within the 60-day period, the application for an exemption                                                    |
| minimum       | application for a new use, which at a minimum requires: (i) That existing data characterizing the safety                                                  |
| exceeds       | study or studies for the new use reasonably exceeds the expected revenue from the new use minus                                                           |
| after         | If FDA receives data  after a manufacturer has begun disseminating information on a                                                                       |
| after         | If FDA receives data  after a manufacturer has begun disseminating information on a                                                                       |
| after         | FDA shall issue such an order only  after it has: (i) Provided notice to the manufacturer                                                                 |
| within        | submit a supplemental application for the new use within 6 months of the date that dissemination can                                                      |
| within        | submit a supplemental application for the new use within  6 months, the manufacturer has not,                                                             |
| within        | submit a supplemental application for the new use within  6 months, the manufacturer has not,                                                             |
| within        | submit a supplemental application for the new use within  6 months, the manufacturer has not,                                                             |
| within        | submit a supplemental application for the new use within  6 months, the manufacturer has not,                                                             |
| within        | submit a supplemental application for the new use within  6 months, the manufacturer has not,                                                             |
| after         | supplemental application within the certified time, or FDA, after an informal hearing, has determined that the manufacturer                               |
| within        | submit a supplemental application for the new use within  6 months, the manufacturer has not,                                                             |
| within        | submit a supplemental application for the new use within  6 months, the manufacturer has not,                                                             |
| within        | the agency had not acted on the application within  60 days after its receipt by FDA;                                                                     |
| after         | not acted on the application within 60 days after  its receipt by FDA;                                                                                    |
| no later than | information, the manufacturer shall comply with the order no later than  60 days after its receipt.                                                       |
| after         | with the order no later than 60 days after  its receipt.                                                                                                  |
| after         | a supplemental application for a new use if, after consulting with the manufacturer that was granted such                                                 |
| within        | paragraph (d) of this section, the manufacturer must, within 60 days of being notified by FDA that                                                        |
| within        | be taken will be sufficiently conspicuous to individuals within  that category of recipients;                                                             |
| before        | If the manufacturer discontinues or terminates a study  before completing it, the manufacturer shall, as part of                                          |
| after         | or disseminated under this part for 3 years after it has ceased dissemination of such information and                                                     |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|:-----------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.0 year   | The manufacturer shall permanently affix the statement to the front of each reprint or copy of an article from a scientific or medical journal and to the front of each reference publication disseminated under this part;                                                                                                                                                                                                                                                                                                                                                                                                            |
|            |               (ii) If applicable, the information is being disseminated at the expense of the manufacturer;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|            |               (iii) If applicable, the names of any authors of the information who were employees of, or consultants to, or received compensation from the manufacturer, or who had a significant financial interest in the manufacturer during the time that the study that is the subject of the dissemination was conducted up through 1 year after the time the article/reference publication was written and published;                                                                                                                                                                                                           |
|            |               (iv) If applicable, a statement that there are products or treatments that have been approved or cleared for the use that is the subject of the information being disseminated; and                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |               (v) The identification of any person that has provided funding for the conduct of a study relating to the new use of a drug or device for which such information is being disseminated; and                                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (2) The official labeling for the drug or device;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|            |               (3) A bibliography of other articles (that concern reports of clinical investigations both supporting and not supporting the new use) from a scientific reference publication or scientific or medical journal that have been previously published about the new use of the drug or device covered by the information that is being disseminated, unless the disseminated information already includes such a bibliography; and                                                                                                                                                                                          |
|            |               (4) Any additional information required by FDA under &#167;&#8201;99.301(a)(2).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 60 day     | (a) Sixty days before disseminating any written information concerning the safety, effectiveness, or benefit of a new use for a drug or device, a manufacturer shall submit to the agency:                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 6.0 month  | If the manufacturer has no knowledge of clinical trial information relating to the safety or effectiveness of the new use or reports of clinical experience pertaining to the safety of the new use, the manufacturer shall provide a statement to that effect;                                                                                                                                                                                                                                                                                                                                                                        |
|            |               (3) An explanation of the manufacturer's method of selecting the articles for the bibliography (e.g., the databases or sources and criteria (i.e., subject headings/keywords) used to generate the bibliography and the time period covered by the bibliography); and                                                                                                                                                                                                                                                                                                                                                    |
|            |               (4) If the manufacturer has not submitted a supplemental application for the new use, one of the following:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (i) If the manufacturer has completed studies needed for the submission of a supplemental application for the new use:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|            |               (A) A copy of the protocol for each completed study or, if such protocol was submitted to an investigational new drug application or an investigational device exemption, the number(s) for the investigational new drug application or investigational device exemption covering the new use, the date of submission of the protocol(s), the protocol number(s), and the date of any amendments to the protocol(s); and                                                                                                                                                                                                 |
|            |               (B) A certification stating that, &#8220;On behalf of [insert manufacturer's name], I certify that [insert manufacturer's name] has completed the studies needed for the submission of a supplemental application for [insert new use] and will submit a supplemental application for such new use to the Food and Drug Administration no later than [insert date no later than 6 months from date that dissemination of information under this part can begin]&#8221;; or                                                                                                                                               |
|            |               (ii) If the manufacturer has planned studies that will be needed for the submission of a supplemental application for the new use:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|            |               (A) The proposed protocols and schedule for conducting the studies needed for the submission of a supplemental application for the new use.                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 36.0 month | The schedule shall include the projected dates on which the manufacturer expects the principal study events to occur (e.g., initiation and completion of patient enrollment, completion of data collection, completion of data analysis, and submission of the supplemental application); and                                                                                                                                                                                                                                                                                                                                          |
|            |               (B) A certification stating that, &#8220;On behalf of [insert manufacturer's name], I certify that [insert manufacturer's name] will exercise due diligence to complete the clinical studies necessary to submit a supplemental application for [insert new use] and will submit a supplemental application for such new use to the Food and Drug Administration no later than [insert date no later than 36 months from date that dissemination of information under this part can begin or no later than such time period as FDA may specify pursuant to an extension granted under &#167;&#8201;99.303(a)];&#8221; or |
|            |               (iii) An application for exemption from the requirement of a supplemental application; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|            |               (5) If the manufacturer has submitted a supplemental application for the new use, a cross-reference to that supplemental application.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 60.0 day   | (d) The 60-day period shall begin when FDA receives a manufacturer's submission, including, where applicable, a certification statement or an application for an exemption.                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 36.0 month | (a) A manufacturer may request, prior to or at the time of making a submission to FDA under &#167;&#8201;99.201, that FDA extend the 36-month time period for completing the studies and submitting a supplemental application for the new use that is the subject of the information to be disseminated.                                                                                                                                                                                                                                                                                                                              |
| 36.0 month | Such request must set forth the reasons that such studies cannot be completed and submitted in a supplemental application within 36 months.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 24.0 month | The requested extension shall not exceed an additional 24 months.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 60.0 day   | Within 60 days after receiving a submission under this part, FDA may:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (1) Determine that the manufacturer does not comply with the requirements under this part and that, as a result, the manufacturer shall not disseminate any information under this part;                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|            |               (2) After providing the manufacturer notice and an opportunity for a meeting, determine that the information submitted regarding a new use fails to provide data, analyses, or other written matter that is objective and balanced and:                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (i) Require the manufacturer to disseminate additional information, including information that the manufacturer has submitted to FDA or, where appropriate, a summary of such information or any other information that can be made publicly available, which, in the agency's opinion:                                                                                                                                                                                                                                                                                                                                  |
|            |               (A) Is objective and scientifically sound;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (B) Pertains to the safety or effectiveness of the new use; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (C) Is necessary to provide objectivity and balance; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|            |               (ii) Require the manufacturer to disseminate an objective statement prepared by FDA that is based on data or other scientifically sound information available to the agency and bears on the safety or effectiveness of the drug or device for the new use; and                                                                                                                                                                                                                                                                                                                                                          |
|            |               (3) Require the manufacturer to maintain records that will identify individual recipients of the information that is to be disseminated when such individual records are warranted due to special safety considerations associated with the new use.                                                                                                                                                                                                                                                                                                                                                                     |
| 60.0 day   | Within 60 days after receiving a submission under this part, FDA shall:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|            |               (1) If the manufacturer has planned studies that will be needed for the submission of a supplemental application for the new use, review the manufacturer's proposed protocols and schedule for completing such studies and determine whether the proposed protocols are adequate and whether the proposed schedule for completing the studies is reasonable.                                                                                                                                                                                                                                                            |
| 36.0 month | (a) Upon review of a drug or device manufacturer's proposed protocols and schedules for conducting studies needed for the submission of a supplemental application for a new use, FDA may, with or without a request for an extension from the manufacturer, determine that such studies cannot be completed and submitted within 36 months.                                                                                                                                                                                                                                                                                           |
| 24.0 month | Extensions under this paragraph shall not exceed 24 months.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 60.0 day   | (a) Within 60 days after receipt of an application for an exemption from the requirement of a supplemental application, FDA shall approve or deny the application.                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 60.0 day   | (1) If FDA does not act on the application for an exemption within the 60-day period, the application for an exemption shall be deemed to be approved.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 6.0 month  | FDA need not provide an opportunity for a meeting if the manufacturer certified that it will submit a supplemental application for the new use within 6 months of the date that dissemination can begin and the noncompliance involves a failure to submit such supplemental application.                                                                                                                                                                                                                                                                                                                                              |
| 6.0 month  | FDA may order a manufacturer to cease disseminating information under this part and to take corrective action if:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |               (1) In the case of a manufacturer that has submitted a supplemental application for the new use, FDA determines that the supplemental application does not contain adequate information for approval of the new use;                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (2) In the case of a manufacturer that has certified that it will submit a supplemental application for the new use within 6 months, the manufacturer has not, within the 6-month period, submitted a supplemental application for the new use;                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (3) In the case of a manufacturer that has certified that it will submit a supplemental application for the new use within 36 months or within such time as FDA has determined to be appropriate under &#167;&#8201;99.303(a) or (b), such manufacturer has not submitted the supplemental application within the certified time, or FDA, after an informal hearing, has determined that the manufacturer is not acting with due diligence to initiate or complete the studies necessary to support a supplemental application for the new use; or                                                                       |
|            |               (4) In the case of a manufacturer that has certified that it will submit a supplemental application for the new use within 36 months or within such time as FDA has determined to be appropriate under &#167;&#8201;99.303(a) or (b), the manufacturer has discontinued or terminated the clinical studies that would be necessary to support a supplemental application for a new use.                                                                                                                                                                                                                                  |
| 6.0 month  | FDA may order a manufacturer to cease disseminating information under this part and to take corrective action if:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |               (1) In the case of a manufacturer that has submitted a supplemental application for the new use, FDA determines that the supplemental application does not contain adequate information for approval of the new use;                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (2) In the case of a manufacturer that has certified that it will submit a supplemental application for the new use within 6 months, the manufacturer has not, within the 6-month period, submitted a supplemental application for the new use;                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (3) In the case of a manufacturer that has certified that it will submit a supplemental application for the new use within 36 months or within such time as FDA has determined to be appropriate under &#167;&#8201;99.303(a) or (b), such manufacturer has not submitted the supplemental application within the certified time, or FDA, after an informal hearing, has determined that the manufacturer is not acting with due diligence to initiate or complete the studies necessary to support a supplemental application for the new use; or                                                                       |
|            |               (4) In the case of a manufacturer that has certified that it will submit a supplemental application for the new use within 36 months or within such time as FDA has determined to be appropriate under &#167;&#8201;99.303(a) or (b), the manufacturer has discontinued or terminated the clinical studies that would be necessary to support a supplemental application for a new use.                                                                                                                                                                                                                                  |
| 36.0 month | FDA may order a manufacturer to cease disseminating information under this part and to take corrective action if:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |               (1) In the case of a manufacturer that has submitted a supplemental application for the new use, FDA determines that the supplemental application does not contain adequate information for approval of the new use;                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (2) In the case of a manufacturer that has certified that it will submit a supplemental application for the new use within 6 months, the manufacturer has not, within the 6-month period, submitted a supplemental application for the new use;                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (3) In the case of a manufacturer that has certified that it will submit a supplemental application for the new use within 36 months or within such time as FDA has determined to be appropriate under &#167;&#8201;99.303(a) or (b), such manufacturer has not submitted the supplemental application within the certified time, or FDA, after an informal hearing, has determined that the manufacturer is not acting with due diligence to initiate or complete the studies necessary to support a supplemental application for the new use; or                                                                       |
|            |               (4) In the case of a manufacturer that has certified that it will submit a supplemental application for the new use within 36 months or within such time as FDA has determined to be appropriate under &#167;&#8201;99.303(a) or (b), the manufacturer has discontinued or terminated the clinical studies that would be necessary to support a supplemental application for a new use.                                                                                                                                                                                                                                  |
| 36.0 month | FDA may order a manufacturer to cease disseminating information under this part and to take corrective action if:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |               (1) In the case of a manufacturer that has submitted a supplemental application for the new use, FDA determines that the supplemental application does not contain adequate information for approval of the new use;                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (2) In the case of a manufacturer that has certified that it will submit a supplemental application for the new use within 6 months, the manufacturer has not, within the 6-month period, submitted a supplemental application for the new use;                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (3) In the case of a manufacturer that has certified that it will submit a supplemental application for the new use within 36 months or within such time as FDA has determined to be appropriate under &#167;&#8201;99.303(a) or (b), such manufacturer has not submitted the supplemental application within the certified time, or FDA, after an informal hearing, has determined that the manufacturer is not acting with due diligence to initiate or complete the studies necessary to support a supplemental application for the new use; or                                                                       |
|            |               (4) In the case of a manufacturer that has certified that it will submit a supplemental application for the new use within 36 months or within such time as FDA has determined to be appropriate under &#167;&#8201;99.303(a) or (b), the manufacturer has discontinued or terminated the clinical studies that would be necessary to support a supplemental application for a new use.                                                                                                                                                                                                                                  |
| 60.0 day   | (1) The application for an exemption had been deemed to be approved because the agency had not acted on the application within 60 days after its receipt by FDA;                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 60.0 day   | If FDA also issues an order to cease dissemination of information, the manufacturer shall comply with the order no later than 60 days after its receipt.                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 60.0 day   | (e) If FDA terminates an approval of an application for an exemption under paragraph (d) of this section, the manufacturer must, within 60 days of being notified by FDA that its exemption approval has been terminated, file a supplemental application for the new use that is the subject of the information being disseminated under the exemption, certify, under &#167;&#8201;99.201(a)(4)(i) or (a)(4)(ii) that it will file a supplemental application for the new use, or cease disseminating the information on the new use.                                                                                                |
| 6.0 month  | The list shall cover articles and reference publications disseminated in the 6-month period preceding the date on which the manufacturer provides the list to FDA;                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (2) A list identifying the categories of health care practitioners, pharmacy benefit managers, health insurance issuers, group health plans, or Federal or State Government agencies that received the articles and reference publications in the 6-month period described in paragraph (b)(1) of this section.                                                                                                                                                                                                                                                                                                          |
| 6.0 month  | The list shall cover articles and reference publications disseminated in the 6-month period preceding the date on which the manufacturer provides the list to FDA;                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (2) A list identifying the categories of health care practitioners, pharmacy benefit managers, health insurance issuers, group health plans, or Federal or State Government agencies that received the articles and reference publications in the 6-month period described in paragraph (b)(1) of this section.                                                                                                                                                                                                                                                                                                          |
| 3.0 year   | (c) A manufacturer shall maintain a copy of all information, lists, records, and reports required or disseminated under this part for 3 years after it has ceased dissemination of such information and make such documents available to FDA for inspection and copying.                                                                                                                                                                                                                                                                                                                                                               |


## Condition

| Condition      | Context                                                                                                                                              |
|:---------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------|
| where          | information on human drugs, including biologics, and devices where the information to be disseminated: (1) Concerns the                              |
| subject to     | of insurance in a State and which is subject to State law which regulates insurance (within the meaning                                              |
| where          | generally available in bookstores or other distribution channels where medical textbooks are sold; (4) Does not focus                                |
| provided that  | statement of intended use for a cleared device, provided that the manufacturer complies with all other relevant requirements                         |
| if             | under this part to be false or misleading if , among other things, the information includes only                                                     |
| when           | other things, the information includes only favorable publications when unfavorable publications exist or excludes articles, reference publications, |
| unless         | derived from clinical research conducted by another manufacturer unless the manufacturer disseminating the information has the permission            |
| unless         | not reflect any systematic attempt to collect data, unless the manufacturer demonstrates to FDA that such reports                                    |
| if             | an article or reference publication is &#8220;unabridged&#8221; only if it retains the same appearance, form, format, content,                       |
| if             | uncleared use or uses, the manufacturer shall mod if y the statement to ident                                                                        |
| if             | or copy of an article from a scient if ic or medical journal and to the front                                                                        |
| if             | or copy of an article from a scient if ic or medical journal and to the front                                                                        |
| if             | or copy of an article from a scient if ic or medical journal and to the front                                                                        |
| unless         | covered by the information that is being disseminated, unless the disseminated information already includes such a bibliography;                     |
| if             | to the front of the disseminated information or, if attached to the back of the disseminated information,                                            |
| where          | that the manufacturer has submitted to FDA or, where appropriate, a summary of such information and any                                              |
| if not         | not limited to, published papers and abstracts, even if not intended for dissemination, and unpublished manuscripts, abstracts, and                  |
| if             | of the protocol for each completed study or, if such protocol was submitted to an investigational new                                                |
| if             | of the protocol for each completed study or, if such protocol was submitted to an investigational new                                                |
| if             | of the protocol for each completed study or, if such protocol was submitted to an investigational new                                                |
| if             | of the protocol for each completed study or, if such protocol was submitted to an investigational new                                                |
| if             | of the supplemental application); and (B) A cert if ication stating that, &#8220;On behalf of [insert manufacturer's                                 |
| when           | (d) The 60-day period shall begin  when FDA receives a manufacturer's submission, including, where applicable,                                       |
| where          | begin when FDA receives a manufacturer's submission, including, where applicable, a certification statement or an application for                    |
| if             | of a supplemental application for the new use. if                                                                                                    |
| if             | the new use, including documentation from prior discussions, if any, with the agency concerning the studies that                                     |
| if             | of a supplemental application for the new use. if                                                                                                    |
| if             | address the possibility of conducting studies in d if ferent populations or of mod                                                                   |
| where          | that the manufacturer has submitted to FDA or, where appropriate, a summary of such information or any                                               |
| when           | of the information that is to be disseminated when such individual records are warranted due to special                                              |
| if             | proposed schedule for completing the studies is reasonable. if                                                                                       |
| if             | FDA shall not if y the manufacturer of its determination; or (2)                                                                                     |
| not subject to | Extensions under this paragraph are  not subject to any time limit, but shall be made before                                                         |
| if             | may grant a manufacturer's request for an extension if FDA determines that the manufacturer has acted with                                           |
| if             | section after the manufacturer has submitted a cert if ication under &#167;&#8201;99.201(a)(4)(ii)(B), or                                            |
| if             | section after the manufacturer has submitted a cert if ication under &#167;&#8201;99.201(a)(4)(ii)(B), or                                            |
| if             | an exemption shall be deemed to be approved. if                                                                                                      |
| if             | FDA may, at any time, terminate such approval if it determines that the requirements for granting an                                                 |
| if             | FDA may, at any time, terminate such approval if it determines that the requirements for granting an                                                 |
| if             | FDA shall not if y the manufacturer                                                                                                                  |
| if             | FDA may grant an application for an exemption if FDA determines that: (1) It would be economically                                                   |
| if             | into compliance with the requirements under this part if the manufacturer's noncompliance constitutes a minor violation of                           |
| if             | need not provide an opportunity for a meeting if  the manufacturer cert                                                                              |
| unless         | effective upon date of receipt by the manufacturer, unless  otherwise stated in such order.                                                          |
| if             | A manufacturer shall not if y FDA immediately                                                                                                        |
| if             | to correct the information that has been disseminated if FDA determines that the new use described in                                                |
| if             | to correct the information that has been disseminated if FDA determines that the new use described in                                                |
| if             | (c) FDA shall not if y the manufacturer                                                                                                              |
| if             | file a supplemental application for a new use if , after consulting with the manufacturer that was                                                   |
| if             | manufacturer must, within 60 days of being not if ied by FDA that its exemption approval has                                                         |
| if             | adulteration, or misbranding of the drug or device if such dissemination fails to comply with section 551                                            |
| unless         | by category, the recipients of the disseminated information, unless FDA requires the manufacturer to retain records identifying                      |
| where          | category only shall: (A) Identify subcategories of recipients where  appropriate (e.g., oncologists, pediatricians, obstetricians, etc.              |
| if             | The list shall also ident if y which category of recipients received a particular                                                                    |
| if             | not limited to, new articles published in scient if ic or medical journals, reference publications, and summaries                                    |
| if             | continues to meet the requirements for such exemption. if                                                                                            |


## Entities

| Entities      | Context                                                                                                                                       |
|:--------------|:----------------------------------------------------------------------------------------------------------------------------------------------|
| Food          | Food  and Drugs.                                                                                                                              |
| Scope         | Scope .                                                                                                                                       |
| New           | (g)  New use means a use that is not included                                                                                                 |
| Health        | Library of Medicine of the National Institutes of Health ; and (5) That is not in the                                                         |
| Such          | Such information shall: (1) Be about a drug or                                                                                                |
| Such          | Such reprint, copy of an article, or reference publication                                                                                    |
| Such          | Such information shall be attached to the front of                                                                                            |
| United States | not have a place of business in the United States , the submission and certification statement or application                                 |
| United States | not have a place of business in the United States , the submission and certification statement or application                                 |
| Information   | be marked as &#8220;Submission for the Dissemination of Information on an Unapproved/New Use.&#8221; The manufacturer shall send              |
| Research      | and Drug Administration, Center for Biologics Evaluation and Research , Document Control Center, 10903 New Hampshire Ave.,                    |
| Rm            | 71,  Rm .                                                                                                                                     |
| G112          | G112 , Silver Spring, MD 20993-0002; (2) For human                                                                                            |
| Research      | regulated by the Center for Drug Evaluation and Research , the Division of Drug Marketing, Advertising, and                                   |
| Advertising   | Evaluation and Research, the Division of Drug Marketing, Advertising , and Communications (HFD-42), Center for Drug Evaluation                |
| Research      | regulated by the Center for Drug Evaluation and Research , the Division of Drug Marketing, Advertising, and                                   |
| Rockville, MD | Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857; or (3) For medical devices, the Promotion                     |
| Rockville, MD | Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857; or (3) For medical devices, the Promotion                     |
| Request       | Request  to extend the time for completing planned studies.                                                                                   |
| Such          | Such request must set forth the reasons that such                                                                                             |
| Request       | of the envelope shall be marked as &#8220; Request for Time Extension&#8212;Dissemination of Information on an Unapproved                     |
| Information   | be marked as &#8220;Request for Time Extension&#8212;Dissemination of Information on an Unapproved Use.&#8221; Application for exemption from |
| Such          | Such evidence shall include an analysis of all data                                                                                           |
| Such          | Such evidence shall include: (A) A description of the                                                                                         |
| Such          | Such evidence shall include an analysis of all data                                                                                           |
| Such          | Such evidence shall establish that, notwithstanding the insufficiency of                                                                      |
| Agency        | Agency  action on a submission.                                                                                                               |
| Such          | Such action may include ordering the manufacturer to cease                                                                                    |


